Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Lithea AB maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action associated with this entity. This single action is being reviewed by 1 distinct examiner located in 1 distinct art unit, showing that the company's current prosecution is focused on a 1 application or a very narrow group of related filings. This structure suggests a highly specialized approach to securing patent rights within the biotechnology sector.
ROGERS, JAMES WILLIAM is identified as the busiest examiner, with 1 busiest examiner pending office action. This count of 1 is identical to the total pending office actions for the portfolio, placing the entirety of the company's current patent office interaction under this specific examiner's review. The alignment of 1 distinct examiner and 1 distinct art unit suggests a streamlined but limited scope of active prosecution at this time. Practitioners managing such a portfolio must focus their efforts on the specific preferences and examination style of this 1 individual.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROGERS, JAMES WILLIAM | 1 | 46.1% | +22.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17665316 | TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES | ROGERS, JAMES WILLIAM | 2d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17665316 | TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES | ROGERS, JAMES WILLIAM | 2d overdue |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17665316 | TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES | ROGERS, JAMES WILLIAM | 1618 | §103§112 | Final Rejection | 2d overdue | Pending | Feb 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLithea AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
James William Rogers has the most, with 1 of Lithea AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
